Table 1.
Baseline characteristics of the randomized patients
| Variables | All, n=78 | Placebo, n=39 | Sevelamer, n=39 |
|---|---|---|---|
| Age, yr | 63±13 | 63±14 | 63±13 |
| Men, n (%) | 55 (71) | 28 (72) | 27 (69) |
| Body mass index, kg/m2 | 28±5 | 28±5 | 28±5 |
| GFR MDRD, ml/min per 1.73 m2 | 27±9 | 28±10 | 25±8 |
| SBP, mmHg | 142±20 | 143±20 | 141±20 |
| DBP, mmHg | 79±10 | 80±10 | 78±10 |
| Serum C-terminal FGF23, RU/ml | 157 (120–241) | 142 (120–221) | 166 (120–249) |
| Serum intact FGF23, pg/ml | 72 (47–103) | 71 (42–118) | 72 (53–109) |
| Serum α-klotho, pg/ml | 809 (674–981) | 784 (648–1060) | 830 (714–927) |
| Serum phosphorus, mg/dl | 3.8±0.5 | 3.9±0.5 | 3.8±0.6 |
| Serum calcium, mg/dl | 9.4±0.4 | 9.3±0.4 | 9.4±0.4 |
| Serum creatinine, mg/dl | 2.6±0.9 | 2.6±0.8 | 2.7±0.9 |
| Serum intact PTH, pg/ml | 97 (61–127) | 103 (71–141) | 91 (58–123) |
| Serum 25 hydroxyvitamin D, ng/ml | 31±12 | 29±11 | 34±18 |
| Serum 1,25 dihydroxyvitamin D, ng/ml | 28 (22–40) | 31 (23–39) | 26 (20–42) |
| CRP, mg/L | 3 (2–8) | 3 (2–4) | 5 (3–10) |
| Serum triglycerides, mg/dl | 137 (93–200) | 151 (97–256) | 136 (89–163) |
| Serum total cholesterol, mg/dl | 182±42 | 183±39 | 179±45 |
| Serum HDL cholesterol, mg/dl | 54±19 | 53±20 | 54±19 |
| Serum LDL cholesterol, mg/dl | 96±39 | 92±39 | 99±40 |
| Serum hemoglobin, g/dl | 12.6±1.4 | 12.5±1.3 | 12.7±1.5 |
| Urinary phosphate-to-urinary creatinine ratio, mmol/mmol | 2.0±0.6 | 2.0±0.5 | 2.0±0.7 |
| Urinary calcium-to-urinary creatinine ratio, mmol/mmol | 0.1±0.1 | 0.1±0.1 | 0.1±0.1 |
| Urinary creatinine, mmol/L | 5.8±2.2 | 5.4±1.8 | 6.2±2.5 |
Data are quoted as the mean±SD for normally distributed variables, the median (interquartile range) for non-normally distributed variables, or the number (percentage) for binary variables. GFR MDRD, GFR calculated with the Modification of Diet in Renal Disease formula; SBP, systolic BP; DBP, diastolic BP; FGF23, fibroblast growth factor 23; RU, relative units; PTH, parathyroid hormone; CRP, C-reactive protein.